# Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

> **NCT02808312** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 57 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)
- Primary Sclerosing Cholangitis (PSC)

## Interventions

- **DRUG:** Cilofexor

## Key facts

- **NCT ID:** NCT02808312
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-13
- **Primary completion:** 2018-10-16
- **Final completion:** 2018-10-16
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808312, "Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02808312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*